Publicaciones (313) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

    Pharmacological Research, Vol. 200

2023

  1. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation

    The Journal of general physiology, Vol. 155, Núm. 1

  2. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  3. An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps

    Cardiovascular Drugs and Therapy, Vol. 37, Núm. 6, pp. 1205-1223

  4. Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated

    European heart journal

  5. Convergent activation of Ca2+ permeability in two-pore channel 2 through distinct molecular routes

    Science signaling, Vol. 16, Núm. 799, pp. eadg0661

  6. Diferencias de sexo en los beneficios de la anticoagulación en pacientes ancianos con fibrilación auricular: un subanálisis del estudio EMERG-AF

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 4, pp. 252-260

  7. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 25, Núm. 4, pp. 1249-1276

  8. Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (European Heart Journal - Cardiovascular Imaging (2022) 23:3 (e333–e465) DOI: 10.1093/ehjci/jeac106)

    European Heart Journal Cardiovascular Imaging

  9. Erratum: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (European Heart Journal—Cardiovascular Pharmacotherapy (2022) 8: 4 (406–419) DOI: 10.1093/ehjcvp/pvac005)

    European Heart Journal - Cardiovascular Pharmacotherapy

  10. Erratum: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (European Heart Journal-Cardiovascular Pharmacotherapy (2022) 8: 1 (85-99) DOI: 10.1093/ehjcvp/pvab018)

    European Heart Journal - Cardiovascular Pharmacotherapy

  11. Herbal medicines for the treatment of cardiovascular diseases: Benefits and risks – A narrative review

    International Journal of Cardiology, Vol. 385, pp. 44-52

  12. How important it is to know the preferences of the diabetic patient

    International Journal of Cardiology

  13. Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial

    Heart rhythm, Vol. 20, Núm. 6, pp. 822-830

  14. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

  15. Sex and gender differences in the treatment of arterial hypertension

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 4, pp. 329-347

  16. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]

    Endocrinologia, Diabetes y Nutricion, Vol. 70, pp. 51-62

  17. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 6, pp. 570-582

2022

  1. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

    European heart journal, Vol. 43, Núm. 41, pp. 4229-4361

  2. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

    European heart journal. Cardiovascular Imaging, Vol. 23, Núm. 10, pp. e333-e465